Using a collective impact approach for surveillance of drug overdoses to inform targeted drug-related prevention, treatment, policy-making, and harm reduction strategies is a core focus of work at the AMA.
The AMA is working to advance a public health approach to surveillance that can inform targeted drug-related prevention, treatment, and policy-making, as well as harm reduction strategies.
The AMA urges additional policy changes to accurately track overdose and mortality trends to provide equitable public health interventions that include comprehensive, disaggregated, racial and ethnic data collection related to testing, hospitalization, and mortality associated with opioids and other substances.
Shift from Response to Prevention
Collective Impact of Stakeholders
Each stakeholder plays an important role in the fight to end the drug overdose epidemic, but when stakeholders collaborate, the impact is far greater. This is true for preventative and treatment measures, policies surrounding overdoses, and surveillance efforts.
AMA prescription drug monitoring program national survey
Physicians and other authorized users queried state prescription drug monitoring programs (PDMPs) more than 910,000,000 times in 2020; more than double compared to 2018.